Multicentre phase II trial of plasminogen activator inhibitor-1 inhibitor (TM5614) plus nivolumab in Japanese advanced melanoma patients: immune resistance remains one of the major efforts in melanoma research

Br J Dermatol. 2024 Oct 17;191(5):654-655. doi: 10.1093/bjd/ljae279.
No abstract available